VICTOR LABRADO: Open Payments
NPI 1629629803 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,237 in 58 payments from 11 companies in 2025. Trend: 2023 $1,133 · 2024 $926 · 2025 $2,237
Food & beverage: $2,237
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 14 | $594 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $489 |
| ABBVIE INC. | 13 | $313 |
| Vanda Pharmaceuticals Inc. | 5 | $230 |
| Supernus Pharmaceuticals, Inc. | 5 | $180 |
| Otsuka America Pharmaceutical, Inc. | 3 | $148 |
| E.R. Squibb & Sons, L.L.C. | 1 | $126 |
| Teva Pharmaceuticals USA, Inc. | 3 | $82 |
| Novo Nordisk Inc | 1 | $29 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
Products named: Auvelity, CAPLYTA, VRAYLAR, FANAPT, Qelbree, REXULTI, COBENFY, UZEDY.
Industry payments across TX — which companies pay providers there.
